Tersis Technologies Announces Strategic Initiatives Designed to Address Global Environmental and Economic Pressures
Brooksville, Florida--(Newsfile Corp. - December 18, 2025) - Tersis Technologies (OTCID: TERS) ("Tersis"), now trading under the ticker TERS, today announced strategic initiatives that place the company at the center of global environmental and economic transformation. The company is advancing integrated systems that support clean energy creation, carbon recovery, soil regeneration, water security, and circular economic development. At a time of accelerating global instability, communit
Agriculture, Energy, Alternative Energy, Health
2025-12-18 9:30 AM EST | Tersis Technologies Inc.
Edison Issues Report on MindMaze Therapeutics (MMTX)
London, United Kingdom--(Newsfile Corp. - December 18, 2025) - Edison issues report on MindMaze Therapeutics (SIX: MMTX). MindMaze Therapeutics is a commercial-stage health technology company pioneering AI-driven digital neurotherapeutic solutions for treatment and recovery after neurological events such as stroke and traumatic brain injury (TBI). Its unique, integrated and coordinated platform spans the full continuum of care. With the US FDA and CE/MDR registrations and a unique US CP
Banking / Financial Services, Computer Hardware, Computer Software, Health
2025-12-18 9:12 AM EST | Edison Group
Restart Life Closes Over-Subscribed Second Tranche Financing
Vancouver, British Columbia--(Newsfile Corp. - December 18, 2025) - Restart Life Sciences Corp. (CSE: HEAL) (FSE: HN30) (OTC Pink: NMLSF) ("Restart Life" or the "Company") announces that further to its news release dated November 12, 2025 and December 5, 2025, the Company has closed the over-subscribed second tranche of its non-brokered private placement for total gross proceeds of CDN$630,000 (the "Placement"). As announced on November 12, 2025, the company intended to raise a total of up t
Technology, Biotechnology, Health
2025-12-18 8:00 AM EST | Restart Life Sciences Corp.
Akanda Corp. Welcomes Momentum Towards Cannabis Reform in the United States
Toronto, Ontario--(Newsfile Corp. - December 18, 2025) - Akanda Corp. (NASDAQ: AKAN) ("Akanda" or the "Company") applauds the recent reports that US President Donald Trump and his administration are considering changes and the reclassification of federal cannabis policy in the USA, including potential rescheduling of cannabis from Schedule I to Schedule III. Schedule III drugs are considered to have a medical value and a lower abuse potential as defined by the Drug Enforcement Administra
Cannabis, Health, Cannabis Cultivator, Cannabis Manufacturer
2025-12-18 7:30 AM EST | Akanda Corp
BioHarvest Sciences Awarded $1.6 Million USD Grant from the Israeli Innovation Authority to Advance Second-Generation Botanical Synthesis Platform
British Columbia and Rehovot, Israel--(Newsfile Corp. - December 18, 2025) - BioHarvest Sciences Inc. (NASDAQ: BHST) (FSE: 8MV0) ("BioHarvest" or the "Company"), a biotechnology company pioneering its proprietary Botanical Synthesis™ platform, today announced that it has been awarded a $1.6 million grant from the Israeli Innovation Authority (IIA). The grant was approved under the IIA's Bio-Convergence
Biotechnology, Pharmaceuticals, Health
2025-12-18 7:30 AM EST | BioHarvest Sciences Inc.
Optimi Health Announces Appointment of New Director
Vancouver, British Columbia--(Newsfile Corp. - December 18, 2025) - Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) ("Optimi" or the "Company"), a Canadian GMP-compliant manufacturer of MDMA and psilocybin, is pleased to announce the appointment of Mr. Jason Mosberian as a director of the Company, effective immediately (the "Appointment"). Mr. Mosberian graduated from the Sauder School of Business and earned his CPA designation in 2011 working in audit in
Biotechnology, Pharmaceuticals, Health, Psychedelics
2025-12-18 7:00 AM EST | Optimi Health Corp.
Therma Bright Inc. Investee Company, InStatin Expands its Inhaled Statin Programs to include COPD (Chronic Obstructive Pulmonary Disease) as its Lead Indication.
Toronto, Ontario--(Newsfile Corp. - December 18, 2025) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) (FSE: JNX0) ("Therma" or the "Company"), a developer and investment partner specializing in advanced diagnostic and medical device technologies, is pleased to provide an update on Investee company, InStatin. InStatin, a biotechnology company developing inhaled statin therapies for respiratory diseases, today reported significant progress from June 2024 through December 2025, despite a
Technology, Biotechnology, Health
2025-12-18 7:00 AM EST | Therma Bright Inc.
DiagnosTear Signs Non-Binding Term Sheet with Sheba Impact and Ramot to Exclusively License New Eye Imaging Technology, CLARIFY, Enabling Needle-Free Blood Count
Vancouver, British Columbia--(Newsfile Corp. - December 17, 2025) - DiagnosTear Technologies Inc. (CSE: DTR) (FSE: X8F) ("DiagnosTear" or the "Company"), a leader in rapid eye based diagnostic technologies, is pleased to announce that the Company has signed a non-binding term sheet with Sheba Impact, the Technology Transfer office ("TTO") of Sheba Medical Center ("Sheba MC"), Israel's largest hospital and one of the world's most innovative clinical research institu
2025-12-17 6:00 PM EST | DiagnosTear Technologies Inc.
TempraMed Expands U.S. Manufacturing Capacity with New Production Facility in Florida
Highlights: Manufacturing site in Florida expands TempraMed's U.S. production footprint Increases capacity to meet rising demand from healthcare organizations, pharmacies, payors, and device manufacturers Shortens delivery timelines and improves service for customers in the United States where majority of devices have been sold to date Reduces COGS through localized production, improved logistics
Technology, Biotechnology, Pharmaceuticals, Health
2025-12-17 5:00 PM EST | TempraMed Technologies Ltd
NervGen Pharma Announces Filing of Form F-10 Registration Statement with The SEC Under MJDS
Vancouver, British Columbia--(Newsfile Corp. - December 17, 2025) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF) ("NervGen" or the "Company"), a clinical-stage biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury (SCI) and other traumatic and neurologic disorders, today announced that it has filed a registration statement on Form F-10 (the "Registration Statement") with the United States Securities and Exchange Commission ("SEC") in accor
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2025-12-17 4:19 PM EST | NervGen Pharma Corp.
Restart Life Announces Food Technology and Research Studies
Vancouver, British Columbia--(Newsfile Corp. - December 17, 2025) - Restart Life Sciences Corp. (CSE: HEAL) (FSE: HN30) (OTC Pink: NMLSF) ("Restart Life" or the "Company") is pleased to provide an update regarding its previously disclosed intention to fund food-related research initiatives (the "Research Initiatives") in support of its expanding portfolio of consumer health and wellness products. The Company is now in a position to allocate capital toward the Resear
Technology, Biotechnology, Health
2025-12-17 12:44 PM EST | Restart Life Sciences Corp.
Adia Labs Launches Turnkey Clinic Model for Chiropractic Practices with BoldMD
Winter Park, Florida--(Newsfile Corp. - December 17, 2025) - Adia Labs, a division of Adia Nutrition Inc. (OTCQB: ADIA), today announced a strategic marketing partnership with BoldMD, a leading medical marketing and AI technology company focused on longevity and wellness. The partnership is designed to accelerate the nationwide expansion of Axia MD's innovative chiropractor-hosted pop-up longevity clinics. This collaboration builds on Adia Labs' recently announced partnership with Axia
Healthcare and Hospitals, Health
2025-12-17 9:48 AM EST | Adia Nutrition Inc.
BioVaxys Announces Positive Phase 1 Clinical Study Results with Maveropepimut-S (MVP-S) in Women with Hormone Receptor Positive/HER2 Negative (HR+/HER2-) Stage II-III Breast Cancer
Vancouver, British Columbia--(Newsfile Corp. - December 17, 2025) - BioVaxys Technology Corp. (CSE: BIOV) (FSE: 5LB) (OTCQB: BVAXF) ("BioVaxys" or the "Company"), a clinical stage biotechnology company focused on developing advanced treatments in oncology, infectious disease, allergy, and other immune diseases based on its DPX™ antigen delivery and immune-educating technology platform, is very pleased to announce positive results from a phase 1 clinical study of maveropepimut-S ("MVP-S"
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2025-12-17 8:00 AM EST | BioVaxys Technology Corp.
Safe Supply Streaming Co Ltd. to Attend Great Plains Tribal Leaders' Health Board in South Dakota
Toronto, Ontario--(Newsfile Corp. - December 17, 2025) - Safe Supply Streaming Co Ltd. (CSE: SPLY) (OTCQB: SSPLF) (FSE: QM4) ("Safe Supply" or the "Company"), a pioneer in health, safety and rapid response technologies, is pleased to announce that it will be attending meetings with the Great Plains Tribal Leaders' Health Board (GPTLHB) in South Dakota, on December 18, 2025. The Great Plains Tribal Leaders' Health Board is a tribally governed public health organization that
2025-12-17 7:11 AM EST | Safe Supply Streaming Co Ltd.
Predictmedix AI Inc - 2025 Year End Corporate Update
Toronto, Ontario--(Newsfile Corp. - December 17, 2025) - Predictmedix AI Inc. (CSE: PMED) (OTC Pink: PMEDF) (FSE: 3QP0) ("Predictmedix" or the "Company") concludes 2025 having delivered a year of disciplined execution across technology development, global investor engagement, and strategic advancement—positioning the Company for a pivotal growth phase in 2026 at the convergence of artificial intelligence, quantum-inspired computation, and digital healthcare. Throughout 2025, Predi
2025-12-17 7:00 AM EST | Predictmedix AI Inc.
Edison Issues Report on Ajax Resources (AJAX)
London, United Kingdom--(Newsfile Corp. - December 16, 2025) - Edison issues report on Ajax Resources (AQSE: AJAX). Although until recently a SPAC listed on the Main Market of the LSE, Ajax has wasted no time in becoming a natural resources company listed on Aquis and executing its strategy to acquire orphaned assets at fire sale prices and bringing them to account rapidly. Its flagship asset, Eureka in north-western Argentina, has never been the subject of modern drilling. However, it
Banking / Financial Services, Computer Hardware, Computer Software, Health
2025-12-16 11:01 AM EST | Edison Group
Mayo Clinic Jacksonville Comes Online as Third Site in Breathe BioMedical's Ongoing Multi-Center Clinical Study to Develop a Breath Test for Early Detection of Breast Cancer in Females with Dense Breasts
New Brunswick and Cambridge, Massachusetts--(Newsfile Corp. - December 16, 2025) - Breathe BioMedical, a company developing a breath analytics platform for early disease detection, today announced the launch of the third site in its large multi-center observational collection protocol study to advance the development of its breath test for the early detection
Technology, Biotechnology, Healthcare and Hospitals, Health
2025-12-16 8:00 AM EST | Breathe BioMedical Inc.
Aleen Inc. Insights: Understanding Your Personal Wellness Patterns
Toronto, Ontario--(Newsfile Corp. - December 16, 2025) - Aleen Inc. (CSE: ALEN.U), a digital wellness company, presents a new Insight post focused on the value of noticing how personal wellness patterns evolve over time. The publication highlights why observing these subtle changes can help individuals better understand themselves, recognize meaningful trends, and build a clearer picture of their daily experiences - without any medical interpretation. Many people move thro
2025-12-16 8:00 AM EST | Aleen Inc.
James Anderson Provides Update on Holdings of MyndTec Inc.
Detroit, Michigan--(Newsfile Corp. - December 15, 2025) - James Anderson (the "Investor") announces update to his ownership of common shares in the capital of MyndTec Inc. (the "Issuer") (the "Common Shares") and common share purchase warrants of the Issuer (the "Warrants"). On December 12, 2025, the Issuer completed the ninth tranche (the "Ninth Tranche") of a private placement of units ("Units") announced on January 30, 2025. 553,926 Units we
Technology, Healthcare and Hospitals, Health
2025-12-15 5:25 PM EST | James Anderson
TempraMed Strengthens Global Intellectual Property Position with Grant of South Korean Patent
Highlights Newly granted patent protects TempraMed's VIVI Box™ proprietary, hassle-free thermal-insulation system and smart-monitoring architecture Expands the Company's ability to adapt its core technology to a wider range of drug categories-from chronic self-injectables to complex biologics Enhances commercialization opportunities and supports strategic engagement with leading appliance manufacturers in
Technology, Biotechnology, Pharmaceuticals, Health
2025-12-15 5:00 PM EST | TempraMed Technologies Ltd